Literature DB >> 11701779

Natural history of multiple sclerosis.

G C Ebers1.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11701779      PMCID： PMC1765574          DOI： 10.1136/jnnp.71.suppl_2.ii16

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  11 in total

1.  The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials.

Authors:  B G Weinshenker; G P Rice; J H Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal:  Brain       Date:  1991-04       Impact factor: 13.501

2.  The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome.

Authors:  B G Weinshenker; G P Rice; J H Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal:  Brain       Date:  1991-04       Impact factor: 13.501

Review 3.  Interferons in the treatment of multiple sclerosis: do they prevent the progression of the disease?

Authors:  G Rice; G Ebers
Journal:  Arch Neurol       Date:  1998-12

Review 4.  Primary progressive multiple sclerosis.

Authors:  A J Thompson; C H Polman; D H Miller; W I McDonald; B Brochet; X Filippi M Montalban; J De Sá
Journal:  Brain       Date:  1997-06       Impact factor: 13.501

5.  The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course.

Authors:  B G Weinshenker; B Bass; G P Rice; J Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal:  Brain       Date:  1989-12       Impact factor: 13.501

6.  Diagnostic brain MRI findings in primary progressive multiple sclerosis.

Authors:  M Kremenchutzky; D Lee; G P Rice; G C Ebers
Journal:  Mult Scler       Date:  2000-04       Impact factor: 6.312

7.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.

Authors:  B G Weinshenker; B Bass; G P Rice; J Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal:  Brain       Date:  1989-02       Impact factor: 13.501

8.  The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis.

Authors:  D A Cottrell; M Kremenchutzky; G P Rice; W J Koopman; W Hader; J Baskerville; G C Ebers
Journal:  Brain       Date:  1999-04       Impact factor: 13.501

9.  Relapses and progression of disability in multiple sclerosis.

Authors:  C Confavreux; S Vukusic; T Moreau; P Adeleine
Journal:  N Engl J Med       Date:  2000-11-16       Impact factor: 91.245

10.  On the pathogenesis of multiple sclerosis. A revised model of the cause(s) of multiple sclerosis, especially based on epidemiological data.

Authors:  J M Minderhoud
Journal:  Clin Neurol Neurosurg       Date:  1994-05       Impact factor: 1.876
View more
  21 in total

Review 1.  Managing MS in a changing treatment landscape.

Authors:  Martin Duddy; Aiden Haghikia; Eleonora Cocco; Christian Eggers; Jelena Drulovic; Olga Carmona; Helene Zéphir; Ralf Gold
Journal:  J Neurol       Date:  2011-03-25       Impact factor: 4.849

2.  Correlates of the timed 25 foot walk in a multiple sclerosis outpatient rehabilitation clinic.

Authors:  Francois A Bethoux; Dylan M Palfy; Matthew A Plow
Journal:  Int J Rehabil Res       Date:  2016-06       Impact factor: 1.479

3.  Decision making in MS: factors affecting engagement in treatment choices.

Authors:  Nils Muhlert
Journal:  Funct Neurol       Date:  2016 Jan-Mar

Review 4.  Application of Disease Etiology and Natural History to Prevention in Primary Health Care: A Discourse.

Authors:  Franklin White
Journal:  Med Princ Pract       Date:  2020-05-18       Impact factor: 1.927

Review 5.  Life issues in multiple sclerosis.

Authors:  Rex D Simmons
Journal:  Nat Rev Neurol       Date:  2010-09-21       Impact factor: 42.937

6.  Emotional and behavioural difficulties in children of parents with multiple sclerosis: a controlled study in Greece.

Authors:  Stavroula Diareme; John Tsiantis; Gerasimos Kolaitis; Spyros Ferentinos; Emmanuel Tsalamanios; Elena Paliokosta; Sophia Anasontzi; Eirini Lympinaki; Dimitris C Anagnostopoulos; Costas Voumvourakis; Georg Romer
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-04-13       Impact factor: 4.785

7.  Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.

Authors:  Ray Gani; Gavin Giovannoni; David Bates; Belinda Kemball; Steve Hughes; John Kerrigan
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

8.  The diagnosis of multiple sclerosis and the clinical subtypes.

Authors:  Barrie J Hurwitz
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

9.  The role of hereditary spastic paraplegia related genes in multiple sclerosis. A study of disease susceptibility and clinical outcome.

Authors:  G C DeLuca; S V Ramagopalan; M Z Cader; D A Dyment; B M Herrera; S Orton; A Degenhardt; M Pugliatti; A D Sadovnick; S Sotgiu; G C Ebers
Journal:  J Neurol       Date:  2007-04-10       Impact factor: 4.849

Review 10.  Modifiable comorbidities and disability in multiple sclerosis.

Authors:  Shannon Overs; Christina M Hughes; Jodie K Haselkorn; Aaron P Turner
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.